GLOBAL INDUCED PLURIPOTENT STEM CELLS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Induced pluripotent stem cells (iPSCs) are a type of pluripotent stem cell that can be generated directly from adult cells. The discovery of induced pluripotent stem cells revolutionized the field of regenerative medicine as it provided an ethically superior alternative to embryonic stem cells. Induced pluripotent stem cells (iPSCs) are adult cells that have been genetically reprogrammed to an embryonic stem cell-like pluripotent state. iPSCs are used in regenerative medicine research to study mechanisms of disease and for drug discovery and toxicity screening. Regenerative properties of iPSCs provide opportunities for developing cell-based therapies. These cells are reprogrammed from their original differentiated adult cells through the introduction or overexpression of key transcription factors that enable them to regress to a state that resembles embryonic stem cells in terms of differentiation potential and expression of pluripotency markers. This technology holds tremendous promise for developing patient and disease specific stem cell models for drug discovery, toxicity screening, and regenerative therapies.

Market Dynamics:

Global induced pluripotent stem cells market is driven by rising prevalence of chronic diseases, increasing adoption of organ transplantation and growing research and development (R&D) investments by biopharmaceutical companies for developing novel stem cell-based therapies. However, high costs that are associated with iPSC research and clinical applications, technical challenges in cell reprogramming and stem cell differentiation are restraining wider market growth. Meanwhile, ongoing advancements in stem cell technologies including establishment of standard culture practices, development of xeno-free reprogramming methods and progress in large-scale stem cell production are expected to offer lucrative growth opportunities for market players.

Key features of the study:

• This report provides an in-depth analysis of the global induced pluripotent stem cells market, and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2024-2031), considering 2023 as the base year.
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global induced pluripotent stem cells market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
• The key companies covered as a part of this study include Takara Bio Inc., Thermo Fisher Scientific, Fujifilm Holdings Corporation, Astellas Pharma, Fate Therapeutics, Ncardia, ViaCyte, Cellular Dynamics International, Lonza, Blueprint Medicines, and Other Prominent Players.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global induced pluripotent stem cells market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global induced pluripotent stem cells market.

Detailed Segmentation:

• By Cell Source:
  • Skin derived iPSCs
  • Blood derived iPSCs
  • Urine Derived iPSCs
  • Hepatocytes derived iPSCs
  • Lung fibroblast derived iPSCs
  • Others (Endothelial cells, Glial Cells, Adipose stem cells etc.)
• By Application:
  • Culture & Maintenance
  • Differentiation
  • Genetic Manipulation & Engineering
  • Characterization & Validation
  • Banking & Storage
  • Others (Reprogramming kits, Analysis software etc.)
• By End User:
  • Hospitals
  • Diagnostics Centers
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations
  • Others (Academic & Research Institutes etc.)
• By Region:
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
• Top Companies in the Global Induced Pluripotent Stem Cells Market
  • Takara Bio Inc.
  • Thermo Fisher Scientific
  • Fujifilm Holdings Corporation
  • Astellas Pharma
  • Fate Therapeutics
  • Ncardia
  • ViaCyte
  • Cellular Dynamics International
  • Lonza
  • Blueprint Medicines
  • Other Prominent Players